[Novel ETO2-GLIS2 fusion and therapeutic strategy in acute megakaryoblastic leukemia]

Med Sci (Paris). 2012 Nov;28(11):1013-6. doi: 10.1051/medsci/20122811025. Epub 2012 Nov 12.

[Article in French]

Authors

Clarisse Thiollier¹, Françoise Pflumio, Paola Ballerini, John D Crispino, Olivier Bernard, Thomas Mercher

Affiliation

¹ Université Paris Diderot, Paris, France.

PMID: 23171910
DOI: 10.1051/medsci/20122811025

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Chromosome Inversion / genetics*
Chromosomes, Human, Pair 16 / genetics*
Humans
Leukemia, Megakaryoblastic, Acute / drug therapy
Leukemia, Megakaryoblastic, Acute / genetics*
Megakaryocytes / metabolism
Megakaryocytes / pathology
Mice
Mice, Inbred NOD
Mice, SCID
Molecular Targeted Therapy
Neoplasm Proteins / antagonists & inhibitors
Neoplasm Proteins / genetics*
Neoplastic Stem Cells / metabolism
Oncogene Proteins, Fusion / antagonists & inhibitors
Oncogene Proteins, Fusion / genetics*
Oncogene Proteins, Fusion / physiology
Xenograft Model Antitumor Assays

Substances

Antineoplastic Agents
ETO2-GLIS2 fusion protein, human
Neoplasm Proteins
Oncogene Proteins, Fusion